AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1693335
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose oral treatment
Trial: 1693335
Drug: Subcutaneous hyposensitization
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous hyposensitization regime
Trial: 606781
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza A/New Jersey/X-53 subunit virus vaccine (100 or 200 CCA units for children ≤9 years; 200 or 400 CCA units for children >9 years), administered intramuscularly in two doses at intervals of four weeks.
Trial: 26226884
Drug: Donepezil (3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (3, 5, and 10 mg)
Trial: 23536583
Drug: Intensive glucose-lowering
RxNorm normalized name: biguanide blood glucose lower drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glucose-lowering therapy (INT)
Trial: 21959068
Drug: Valerian (255
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian (255 mg, 3 times daily for 3 days)
Trial: 18810398
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue (MB) 500 mg orally
Trial: 18810398
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue (MB) 500 mg orally combined with chloroquine (CQ) 750 mg
Trial: 18810398
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue (MB) 50 mg intravenous (i.v.)
Trial: 18810398
Drug: Chloroquine (CQ)
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine (CQ) 750 mg administered orally alone
Trial: 17971947
Drug: ADV 10
RxNorm normalized name: ADV-TK
DrugBank: Aglatimagene besadenovec (DB15074)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADV 10 mg/d for 48 weeks
Trial: 17971947
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 24 weeks followed by ADV 10 mg/d for 24 weeks
Trial: 15512809
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg valacyclovir orally every 8 h
Trial: 15512809
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg valacyclovir orally every 8 h
Trial: 11368294
Drug: ZD1839 (100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZD1839 (100mg once daily for 3 days)
Trial: 11368294
Drug: Single 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 50mg dose of ZD1839 with food
Trial: 9487372
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose total-body irradiation (STBI) - 10 Gy to midplane, 8 Gy to lungs
Trial: 9487372
Drug: LOW instantaneous
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOW instantaneous dose rate group (< or = 0.048 Gy/min)
Trial: 9487372
Drug: MEDIUM instantaneous
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDIUM instantaneous dose rate group (> 0.048 and < or = 0.09 Gy/min)
Trial: 9487372
Drug: HIGH instantaneous
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIGH instantaneous dose rate group (> 0.09 Gy/min)
Trial: 9487372
Drug: Treatment after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment after 1985
Trial: 9487372
Drug: Cataract incidence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cataract incidence influenced by instantaneous dose rate
Trial: 8306272
Drug: 131I-Mu-9 immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 131I-Mu-9 immunoglobulin G
Trial: 8306272
Drug: Both 131I-Mu-9
RxNorm normalized name: iobenguane (131I)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both 131I-Mu-9 immunoglobulin G and 131I-F(ab')2
Trial: 3178928
Drug: Maxepa (3.24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxepa (3.24 g eicosapentaenoic acid and 2.16 g docosahexaenoic acid per day)
Trial: 824725
Drug: Diftalone 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diftalone 500 mg/day
Trial: 824725
Drug: Indomethacin 50-75
RxNorm normalized name: indomethacin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 50-75 mg/day initially and 100 mg/day subsequently
Trial: 31118245
Drug: Efgartigimod (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efgartigimod (10 mg/kg IV)
Trial: 28378467
Drug: Ephedrine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (6 mg boluses)
Trial: 28378467
Drug: Phenylephrine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (50 μg boluses)
Trial: 24382638
Drug: Telaprevir (TVR)
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telaprevir (TVR) 750 mg q8h plus peginterferon (180 μg/week) and ribavirin (1,000-1,200 mg/day)
Trial: 21500996
Drug: Estroprogestagen therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estroprogestagen therapy (EP)
Trial: 11734711
Drug: Serogroup B
RxNorm normalized name: Meningococcus serogroup B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serogroup B meningococcal vaccine VA‐MENGOC‐BC (2 doses)
Trial: 11734711
Drug: Serogroup B
RxNorm normalized name: Meningococcus serogroup B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serogroup B meningococcal vaccine VA‐MENGOC‐BC (3 doses)
Trial: 11734711
Drug: Serogroup B
RxNorm normalized name: Meningococcus serogroup B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serogroup B meningococcal vaccine VA‐MENGOC‐BC
Trial: 9403267
Drug: Povidone-iodine (PVP-I)
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine (PVP-I) ethanol solution
Trial: 29868911
Drug: High-nitrate (HN)
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-nitrate (HN) vegetables (∼200 g/d; ∼150 mg nitrate/d)
Trial: 29868911
Drug: Low-nitrate (LN)
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-nitrate (LN) vegetables (∼200 g/d; ∼22 mg nitrate/d)
Trial: 29868911
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no increase in vegetables; ∼6 mg nitrate/d)
Trial: 23553866
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg fluoride
Trial: 23553866
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg fluoride
Trial: 23553866
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg fluoride
Trial: 19682880
Drug: Escin (60mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escin (60mg daily, 30mg every 12 hours for 2 months)
Trial: 15826880
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplementation (5 mg daily, n = 36)
Trial: 12812355
Drug: Mefloquine-artesunate (MQ-AS)
RxNorm normalized name: artesunate and mefloquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine-artesunate (MQ-AS) combination therapy (MQ 15 mg/kg plus AS 4 mg/kg/day for three days)
Trial: 7786658
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 infusion
Trial: 21699364
Drug: Vaseline® cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaseline® cream (placebo)
Trial: 15005829
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea (caffeine 104 mg/d, catechins 573 mg/d, 323 mg epigallocatechin gallate)
Trial: 8216453
Drug: Gel formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel formulation (Iprogel)
Trial: 8216453
Drug: Hydrophilic ointment
RxNorm normalized name: HYDROPHILIC OINTMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrophilic ointment
Trial: 8216453
Drug: Emulsion cream
RxNorm normalized name: propofol lipid emulsion Injection [Propoven]
DrugBank: Coconut oil (DB14322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emulsion cream (reference product)
Trial: 29940521
Drug: Psychoeducational Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational Cognitive Behavioural Group Therapy (PCBT-G)
Trial: 29940521
Drug: PCBT-G plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCBT-G plus 16 outpatient individual treatment sessions (PCBT-G+I)
Trial: 29940521
Drug: PCBT-G and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCBT-G and PCBT-G+I
Trial: 29940521
Drug: PCBT-G+I
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCBT-G+I
Trial: 29940521
Drug: PCBT-G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCBT-G
Trial: 27136509
Drug: Cold water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold water immersion (8.9±0.6°C; 9 min with 1 min out of water, repeated twice)
Trial: 15752125
Drug: Topical calcipotriol
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical calcipotriol (0.005%) applied twice daily
Trial: 1514500
Drug: Placebo (matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matched to nifedipine doses)
Trial: 6469553
Drug: Clorurated aminoacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clorurated aminoacid solution (10% solution, 1 liter daily)
Trial: 6469553
Drug: Acetated aminoacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetated aminoacid solution (10% solution, 1 liter daily)
Trial: 31448837
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + AM (375 mg amoxicillin and 250 mg metronidazole, 8/8 hours, 7 days)
Trial: 27505191
Drug: Educational video
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational video about generic medicines
Trial: 27505191
Drug: Generic ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Generic ibuprofen
Trial: 22591195
Drug: CK‐2017357 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CK‐2017357 at 250 mg
Trial: 22591195
Drug: CK‐2017357 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CK‐2017357 at 500 mg
Trial: 20177164
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBO therapy)
Trial: 15290118
Drug: Tetrahydrobiopterin (BH4)
RxNorm normalized name: 6R-BH4
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tetrahydrobiopterin (BH4) 10 mg kg(‐1) body weight over 30 min
Trial: 10202392
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g mixed tea oral administration and topical treatment
Trial: 10202392
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and glycerin treatment
Trial: 8748361
Drug: Glutamine-supplemented enteral
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine-supplemented enteral nutrition (0.35 g of glutamine/kg body weight per day)
Trial: 8748361
Drug: Isonitrogenous formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isonitrogenous formula (0.05 g of glutamine/kg body weight per day)
Trial: 2220176
Drug: Norethisterone acetate
RxNorm normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norethisterone acetate (NEA) therapy, 50 mg/day for 6 months followed by a 6-month pause, continued for up to 5 years post-op.
Trial: 2220176
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no NEA therapy) after surgery.
Trial: 2220176
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no NEA therapy) after irradiation.
Trial: 2220176
Drug: Norethisterone acetate
RxNorm normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norethisterone acetate (NEA) therapy.
Trial: 730416
Drug: Hydrochlorothiazide +
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide + Amiloride (50 + 5 mg)
Trial: 30626425
Drug: Stratification based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stratification based on levels of CAFs at diagnosis and their variations after therapy
Trial: 29980224
Drug: Decrease in
RxNorm normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decrease in daily GH dose (IGF‐1 target level of -2 to -1 SDS)
Trial: 29980224
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in daily GH dose (IGF‐1 target level of 1 to 2 SDS)
Trial: 29980224
Drug: Decrease in
RxNorm normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decrease in IGF‐1 levels in females within the low treatment arm
Trial: 27713968
Drug: Whole natural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole natural almonds (42 g per day)
Trial: 27713968
Drug: Whole roasted
RxNorm normalized name: Coffea arabica seed, roasted
DrugBank: Coffea arabica seed, roasted (DB15603)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole roasted almonds (42 g per day)
Trial: 27713968
Drug: Chopped almonds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chopped almonds (42 g per day)
Trial: 27713968
Drug: Almond butter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almond butter (42 g per day)
Trial: 27713968
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 g per day)
Trial: 10517189
Drug: Rifampicin 600
RxNorm normalized name: Rifampicin 600 mg powder for solution for infusion vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 600 mg/day and doxycycline 200 mg/day for 45 days (group 1)
Trial: 10517189
Drug: Rifampicin 600
RxNorm normalized name: Rifampicin 600 mg powder for solution for infusion vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 600 mg/day and ciprofloxacin 1 g/day for 30 days (group 2)
Trial: 30944968
Drug: Oral dissolution
RxNorm normalized name: Witch Hazel 30 mg in 30 mL TOPICAL PATCH [LEADERS INSOLUTION COCONUT LIFTING RECOVERY MASK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dissolution therapy (ODT)
Trial: 30944968
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (ODT + SWL)
Trial: 30536479
Drug: cis100+RT (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cis100+RT (high-dose cisplatin 100 mg/m2 on days 1, 22, and 43)
Trial: 30536479
Drug: cis40+ART (intermediate-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cis40+ART (intermediate-dose cisplatin weekly 40 mg/m2)
Trial: 25824211
Drug: Oritavancin 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oritavancin 1,200 mg single dose
Trial: 21851906
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg three times daily for 14 days
Trial: 19724269
Drug: Routine weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Routine weekly GMA (one session per week)
Trial: 8922243
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and limited field irradiation
Trial: 6354209
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg tolbutamide injected i.v. every four hours
Trial: 31068943
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of miR-181a-5p and miR-155-5p expression post-transplantation
Trial: 18580589
Drug: Panax ginseng
RxNorm normalized name: Panax Ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panax ginseng powder (4.5 g/d) for 12 weeks
Trial: 18580589
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no ginseng treatment)
Trial: 6837492
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (similar vitamin and mineral supplements without added zinc)
Trial: 30952500
Drug: Quadrivalent meningococcal
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent meningococcal conjugate vaccine (MCV)
Trial: 22188747
Drug: Topical capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical capsaicin (200 μl, 5%)
Trial: 20171421
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of clopidogrel 75-mg tablets
Trial: 20171421
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of clopidogrel 75-mg tablets
Trial: 17763408
Drug: Continuous-sequential estrogen-progestogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous-sequential estrogen-progestogen regimen (n = 52)
Trial: 11118919
Drug: SonoVue (Bracco)
DrugBank: Sulfur hexafluoride (DB11104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SonoVue (Bracco) 0.3 ml
Trial: 11118919
Drug: SonoVue (Bracco)
DrugBank: Sulfur hexafluoride (DB11104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SonoVue (Bracco) 0.6 ml
Trial: 11118919
Drug: SonoVue (Bracco)
DrugBank: Sulfur hexafluoride (DB11104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SonoVue (Bracco) 1.2 ml
Trial: 11118919
Drug: SonoVue (Bracco)
DrugBank: Sulfur hexafluoride (DB11104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SonoVue (Bracco) 2.4 ml
Trial: 31818310
Drug: Psychosomatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosomatic therapy in addition to usual care
Trial: 27066903
Drug: Conventional stented
RxNorm normalized name: castor fiber scent gland secretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional stented biological prosthesis (Soprano LivaNova)
Trial: 25246162
Drug: Sublingual zolpidem
RxNorm normalized name: zolpidem Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual zolpidem tartrate tablet (ZST) 3.5 mg in elderly subjects
Trial: 25246162
Drug: Sublingual zolpidem
RxNorm normalized name: zolpidem Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual zolpidem tartrate tablet (ZST) 3.5 mg in elderly males
Trial: 25246162
Drug: Sublingual zolpidem
RxNorm normalized name: zolpidem Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual zolpidem tartrate tablet (ZST) 3.5 mg in elderly females
Trial: 25246162
Drug: Sublingual zolpidem
RxNorm normalized name: zolpidem Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual zolpidem tartrate tablet (ZST) 3.5 mg in non-elderly subjects
Trial: 25246162
Drug: Sublingual zolpidem
RxNorm normalized name: zolpidem Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual zolpidem tartrate tablet (ZST) 1.75 mg and 3.5 mg in elderly subjects
Trial: 25246162
Drug: Sublingual zolpidem
RxNorm normalized name: zolpidem Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual zolpidem tartrate tablet (ZST)
Trial: 19641358
Drug: Alfuzosin XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin XL 10 mg once daily for 2 days
Trial: 17726350
Drug: Operative and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative and pharmaceutical approaches for treatment of infection stones
Trial: 17726350
Drug: Metaphylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaphylactic treatment
Trial: 12755527
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of recombinant Hepatitis B vaccine
Trial: 12755527
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of recombinant Hepatitis B vaccine
Trial: 10338107
Drug: Piracetam 4.8g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam 4.8g daily for 12 weeks
Trial: 10338107
Drug: Piracetam 12g
DrugBank: Piracetam (DB09210)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam 12g intravenous bolus, 12g daily for 4 weeks, and 4.8g daily for a further 8 weeks
Trial: 10338107
Drug: Piracetam treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam treatment within 7 hours of stroke onset
Trial: 1928712
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no rHuEPO treatment)